Insulet Co. (NASDAQ:PODD) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company trimmed its holdings in Insulet Co. (NASDAQ:PODD) by 9.8% during the third quarter, HoldingsChannel.com reports. The fund owned 50,196 shares of the medical instruments supplier’s stock after selling 5,475 shares during the period. The Manufacturers Life Insurance Company’s holdings in Insulet were worth $11,683,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. QRG Capital Management Inc. acquired a new stake in Insulet in the third quarter valued at about $297,000. Diversified Trust Co raised its holdings in shares of Insulet by 90.9% in the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock worth $1,842,000 after acquiring an additional 4,348 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its holdings in Insulet by 65.8% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 8,812 shares of the medical instruments supplier’s stock valued at $1,778,000 after purchasing an additional 3,497 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in Insulet by 38.8% during the second quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier’s stock worth $36,202,000 after acquiring an additional 50,101 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Insulet by 0.9% during the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after purchasing an additional 3,113 shares during the last quarter.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $266.49 on Tuesday. The stock’s fifty day simple moving average is $244.40 and its 200 day simple moving average is $214.37. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $18.69 billion, a price-to-earnings ratio of 45.68, a PEG ratio of 4.08 and a beta of 1.22. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $279.40.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Citigroup lifted their price target on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Morgan Stanley lifted their price objective on shares of Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Barclays increased their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. BTIG Research raised their price objective on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Piper Sandler boosted their price target on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.